Literature DB >> 3096366

Disappearance of factor VIII:C antibodies in patients with haemophilia A upon frequent administration of factor VIII in intermediate or low dose.

E F Van Leeuwen, E P Mauser-Bunschoten, P J Van Dijken, A J Kok, E J Sjamsoedin-Visser, J J Sixma.   

Abstract

In 18 haemophilia A patients with antibodies against factor VIII:C (F VIII:c) the effect of regular treatment with factor VIII (F VIII) in intermediate or low dose was studied. All patients with previous maximal F VIII:c antibody levels between 5 and 60 Bethesda Units per millilitre (BU/ml) showed a decrease of antibody level and normal F VIII recovery within 1-2 months. From nine patients with previous maximal antibody levels above 60 BU/ml four showed a decrease of antibody level within 2-26 months. In four young patients F VIII prophylactic therapy was started or continued as soon as there was evidence of F VIII:c antibody activity. In three of these patients F VIII recovery normalized within a few months.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3096366     DOI: 10.1111/j.1365-2141.1986.tb04122.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

Review 1.  Hemophilia treatment in historical perspective: a review of medical and social developments.

Authors:  F R Rosendaal; C Smit; E Briët
Journal:  Ann Hematol       Date:  1991-02       Impact factor: 3.673

2.  Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies.

Authors:  J G Gilles; J M Saint-Remy
Journal:  J Clin Invest       Date:  1994-10       Impact factor: 14.808

Review 3.  State of care for hemophilia in pediatric patients.

Authors:  Elena Santagostino; Alessandro Gringeri; Pier M Mannucci
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 4.  Treatment strategies in children with hemophilia.

Authors:  Pia Petrini
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

5.  Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A.

Authors:  J G Gilles; B Desqueper; H Lenk; J Vermylen; J M Saint-Remy
Journal:  J Clin Invest       Date:  1996-03-15       Impact factor: 14.808

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.